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ABSTRACT 
BACKGROUND: Fever and neutropenia (FN) is a common precipitant for 
hospitalization among children with cancer, but hospital utilization trends are not well 
described. This study describes national trends for hospital discharges for FN among 
children with cancer for the year 2012, compared to our previous analysis from 2009. 
METHODS: Data were analyzed from the Kids’ Inpatient Database (KID), an all-payer 
US hospital database, for 2012. Pediatric patients with cancer who had a discharge for FN 
were identified using: age ≤ 19 years, urgent or emergent admit type, non-transferred, and 
a combination of ICD-9-CM codes for fever and neutropenia. We evaluated factors 
associated with a “short length of stay” (SLOS). Sampling weights were used to permit 
national inferences.  
RESULTS: In 2012, children with cancer accounted for 1.8% of pediatric hospital 
discharges (n=120,675), with 12.2% (n=13,456) of cancer-related discharges meeting FN 
criteria. Two-fifths of FN discharges had a SLOS, which accounted for $91 million (2015 
US$) in hospital charges. The majority had no serious infections; most common 
infections were viral infection (9.6%) or upper respiratory infection (9.6%). Factors 
significantly associated with SLOS included having a diagnosis of ear infection 
(OR=1.54, CI 1.16-2.03), soft tissue sarcoma (OR=1.47, CI 1.10-1.95), and Hodgkin 
lymphoma (OR 1.51, CI 1.09-2.10), as compared with not having those diagnoses.  
CONCLUSION: SLOS admissions continue to be rarely associated with serious 
infections, but contribute substantially to the burden of hospitalization for pediatric FN. 
Implementation of risk stratification schemas to identify patients who meet low risk 
criteria may decrease financial burden.  
National	Discharges	for	Peds	Ca	FN	Update	
	
3
Introduction 
Among pediatric patients with cancer, substantial research exists related to the 
risk stratification, prevention and treatment of fever and neutropenia (FN).[1] FN 
continues to be a common and potentially life-threatening complication of 
chemotherapy[2,3], requiring urgent evaluation and hospitalization.[4,5] Evidence shows 
that some pediatric patients with cancer who develop FN could be treated as outpatients 
or have an early discharge or even be treated as an outpatient.[6-8] Adoption of these 
practices would require institution specific systems to be in place for risk stratification 
and outpatient monitoring, with consideration for patient travel and social 
circumstances.[9] 
Evaluation of the impact of FN on health care utilization in the United States (US) 
could lead to improved insight into both hospital- and patient-level factors that impact 
length of stay. In our previous study of pediatric patients with cancer who were 
discharged from the hospital with FN, we examined factors associated with a “short 
length of stay” (SLOS) of 3 days or less. We analyzed a nationally representative 
database, the Healthcare Cost and Utilization Project Kids Inpatient Database for 2009, 
and found that SLOS discharges contributed substantially to the burden of hospitalization 
for pediatric FN, but were rarely associated with serious infections. This supports the 
need for continued evaluation of the financial and resource usage by hospital systems, 
insurance payers, and the patients and families these hospitalizations impact.  
The objective of this study was to further characterize discharges for children with 
cancer who are admitted non-electively and discharged with a diagnosis of fever and 
neutropenia, across the United States, utilizing the most recent pediatric hospitalization 
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data from 2012. Understanding the national patterns of health care usage for pediatric 
patients with FN could provide insight into national adoption of alternative management 
practices for FN among children with cancer.  
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Materials and Methods 
Study Design and Setting 
We identified pediatric patients with cancer admitted for FN from a cross-
sectional analysis of pediatric discharges in 2012, using the Healthcare Cost and 
Utilization Project’s (HCUP) Kids’ Inpatient Database (KID), compiled by the Agency 
for Healthcare Research and Quality (AHRQ).[10] The KID is a nationally representative 
database that samples 80% of pediatric discharges and 10% of uncomplicated births from 
both teaching and non-teaching hospitals. This dataset has been compiled every third year 
since 1997.  Our original analysis utilized data from the 2009 KID.[11] For the current 
analysis we utilized data from the most recently available calendar year (2012). 
The KID is designed to provide the statistical power to detect and evaluate rare 
conditions among hospitalized children.  Multiple publications have utilized the KID to 
examine hospitalization patterns of care for children in the US.[12-16] The KID include 
data elements such as International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes, length of stay (LOS), patient demographic 
characteristics, and hospital charges per episode of care. 
In an effort to facilitate research utilizing ICD-9-CM codes, HCUP developed the 
Clinical Classification Software (CCS), which can groups thousands of ICD-9-CM codes 
into 260 mutually exclusive diagnostic groups.(Elixhauser). Several other publications 
have utilized CCS codes to analyze administrative data specific to children with 
cancer.(Mueller NEDS, Mueller KID, Russell H, Goudie Pediatrics) It is imperative to 
recognize that administrative data is presumed to be the diagnoses provided by clinical 
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providers or staff. For this manuscript, CCS codes are utilized for the grouping of patients 
by type of cancer and to identify co-occuring infections (See Supplemental).   
Identification of Cases  
In keeping with our earlier analysis, we determined hospitalizations for pediatric 
patients with cancer using the HCUP CCS codes. Pediatric patients with cancer were 
defined as those encounters having a CCS codes between 11-45, which encompass all 
types of malignancies. We chose to exclude transfers from all analyses in order to assess 
LOS accurately and to avoid duplicate encounters for the same episode of care (since 
patient level identifiers are not available in this dataset). Patients who died were included 
in our analyses.  
Outcome and Explanatory Variables  
As was done in our previous analysis, we chose to capture patients who were 
admitted due to the presence of fever in the setting of neutropenia, rather than those who 
may have had a fever during the course of their inpatient stay for chemotherapy.  This 
decision was made in order to focus on the population of patients where outpatient 
management could have been a consideration. We defined a discharge encounter for 
“fever and neutropenia” (FN) using the following criteria: age ≤19 years, admit type 
either urgent or emergent (i.e., excluded elective admissions), and a combination of ICD-
9-CM discharge diagnosis of fever (780.6, .60, .61) and “neutropenia” (neutropenia 
[288.0], pancytopenia [284.1], or decreased white blood cell count [112.5]) in any of the 
discharge diagnosis fields.  
Co-occurring infections were evaluated by ranking the frequency of all CCS 
codes for infections.  We then included the 10 most common CCS infectious diagnoses 
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(see Supplemental table) as separate variables in our analyses: septicemia (CCS code 2), 
viral infection (7), bacterial infection (3), fungal infection (4), upper respiratory infection 
(126), intestinal infection (135), pneumonia (122), skin infection (197), urinary tract 
infection (159), and ear infection (92).  
The primary outcomes of interest were factors associated with discharges that had 
SLOS of 3 days or less.  The duration of three days was chosen in order to evaluate 
patients whose hospital stay would have been approximately 48 hours, since hospital 
days are counted when they cross midnight. Therefore a patient admitted later in the day 
could spend only 48 hours in the hospital, but their LOS would be counted as 3 days.  
Secondary outcomes for FN discharges, derived from variables available in the 
KID, included population-adjusted frequency of discharges, average LOS, proportion of 
encounters with infectious diagnoses, and mean and total charges by length of stay 
categories.  
Data Analyses 
Discharges within the KID are weighted based on the sampling scheme in order to 
permit inferences for a nationally representative population. HCUP provides 
supplementary sampling and weighting details.[10] Statistical analyses were performed 
using STATA version 13.0 (Stata Corp, College Station, Texas). Survey estimation 
commands (SVY commands) in STATA were used to incorporate the KID sample design 
variables. The following variables were used for survey estimation: “HOSPID” for 
cluster, “KID_STRATUM” for stratum and “DISCWT” for sample weight. All data are 
presented as weighted values to represent the nationally representative population, unless 
specified otherwise. The 2012 KID data contains over 3 million unweighted discharges 
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that, after application of the survey weights, represented over 6.5 million weighted 
discharges in the population. Our analysis was based on de-identified national data and 
was therefore considered exempt from human subjects review by the Indiana University 
Medical Institutional Review Board. 
We utilized descriptive statistics to determine the characteristics of FN discharges 
by gender, age, race/ethnicity, and primary payer type, hospital teaching and location 
status, and hospital Census region.  The frequency of FN discharges was described as the 
rate of discharges per 100,000 US children per year, using national Census data for 
2012.[17] Census data were chosen as the denominator due to the fact that prevalence of 
pediatric patients with cancer is not well described. Hospital charges were recalculated 
from 2012 US dollar ($) to 2015 US dollar using the Consumer Price Index.[18]  
A weighted multivariate logistic regression model, utilizing the HCUP provided 
weights to produce nationally representative results, was performed to estimate factors 
associated with a SLOS among pediatric oncology encounters for FN; statistical weights 
were used to account for clustering of patients by hospital.  The explanatory variables for 
the regression model were selected a priori based on hypothesized clinical relevance and 
were consistent with our previous analysis, which included: patient’s age, gender, 
primary expected payer, median household income for the patient’s zip code, hospital 
location and teaching status, hospital Census region, dichotomous variables for the 
presence or absence of each of the top 10 most common cancer diagnoses, and 
dichotomous variables for types of infections. We hypothesized that hospital level and 
sociodemographic factors impact the decision-making regarding length of stay for 
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patients hospitalized with FN. Statistically significant associations were determined if p-
value was less than 0.05.  
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Results 
Characteristics of the study population 
In 2012, there were a total of 6,675,222 weighted US pediatric discharges in the 
KID.  Within those, 1.8% (n=120,675) had a diagnosis of cancer. According to the HCUP 
classification system, 54.5% (n=60,241) of pediatric cancer patient hospitalizations had 
non-elective admissions (coded as either emergent or urgent) that did not include a 
transfer.  Among non-transferred discharges for pediatric patients with cancer, 12.2% 
(n=13,456) met the criteria for FN; this accounted for 22.3% of all non-elective, non-
transferred pediatric cancer discharges.  Only 0.9% (n=1,015) of non-transferred inpatient 
discharges for pediatric patients with cancer ended in death, and only 65 (0.5%) that were 
pediatric FN discharges. 
The characteristics of the discharges for pediatric patients with cancer that met FN 
criteria are presented in Table I.  The majority of patients with FN discharges were 
between the ages of 0-9 years, which was higher than the proportion among overall 
pediatric cancer discharges for patients between 0-9 years of age.  The population of FN 
discharges were predominantly male and non-Hispanic white race.  Most FN encounters 
had insurance coverage, with private greater than public insurance.  Additionally, the 
proportion of patient discharges with a diagnosis of acute lymphoblastic leukemia (ALL) 
was higher among the FN discharges (43.6%) compared to the overall sample (26.9%).   
In 2012, population-adjusted FN discharges among all pediatric patients with 
cancer occurred at a rate of 16.3 per 100,000 US children.  During 2012, FN discharges 
for pediatric patients with cancer represented 100,845 total inpatient days (compared with 
823,868 total days for all pediatric cancer discharges). 
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Discharge characteristics for pediatric FN discharges 
The average LOS for FN discharges was 7.5 days, and 39% of discharges had a 
SLOS (n=5,230). The most common infections among those with a SLOS were viral 
infection (9.6%) or upper respiratory infection (9.6%), but 66.4% had no infection 
identified. Conversely for patient discharges with a LOS greater than 3 days, the most 
commonly associated infections were septicemia (15.5%), viral infection (12.1%), 
bacterial infection (11.4%), and fungal infection (9.2%) (Table II).  
Charges for pediatric FN discharges 
The mean hospital charge was $65,536 for FN discharges among pediatric 
patients with cancer, with the total charges of about $881 million (Table III).  The mean 
charges varied by LOS category with the average charge for a SLOS being $17,437 
versus greater than 3 days was $96,023.  There was a difference of $1,261 between the 
mean daily charges for those patients with a SLOS versus those with a LOS greater than 
3 days. SLOS discharges accounted for $91.2 million in charges for 2012.  
Factors associated with a SLOS for pediatric FN discharges 
In the multivariate analysis (Table IV), factors associated with significantly 
increased odds of a SLOS for FN included having a diagnosis of an ear infection 
(OR=1.54, CI 1.16-2.03), soft tissue sarcoma (OR=1.47, CI 1.10-1.95), and Hodgkin 
lymphoma (OR=1.51, CI 1.09-2.10) as compared with not having those diagnoses. 
Conversely, socio-demographic factors associated with not having a SLOS included non-
white race (Black OR=0.78, CI 0.65-0.94; Hispanic OR=0.85, CI 0.72-0.99) versus white 
race, and having Healthcare Cost and Utilization Project designated “Other” payer 
(OR=0.74, CI 0.59-0.94) versus private insurance.  
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Discussion 
 This study provides the most recent nationally representative analysis of inpatient 
hospital discharges for FN among pediatric patients with cancer in the US.  Overall, 
among non-elective and non-transferred discharges, we found that in both 2009 and 2012 
about 1 of every 5 pediatric cancer-associated hospital discharges are related to FN. 
Among FN discharges, in both years two-fifths had a SLOS; yet hospital charges were up 
from $65.5 million in 2009 to $91.2 million in 2012 (expressed in 2015 US$). An 
increased odds of having a SLOS in 2012 were found among patients with ear infections, 
soft tissue sarcoma or Hodgkin lymphoma. Conversely, non-white race and “Other 
payer” were found to have decreased odds of a SLOS. This data emphasizes the 
continued need to investigate alternate methods of caring for children with cancer who 
experience FN, especially for those without serious infections.  
 FN remains a common reason for hospitalization among children with cancer 
accounting for 12.2% of discharges, up from 10.1% in 2009.[11] Similarly, the rate of FN 
discharges among the US population (age-adjusted) increased from 13.4 to 16.3 per 
100,000 US children. The total number of inpatient days has increased dramatically from 
79,870 to 100,845 as well. This increase cannot be fully explained by changes in the 
incidence or improvements in treatment intensity and cure rates over this relatively short 
time frame based on most recent statistics.[19] A significant body of literature supports 
risk stratification schemas to decrease hospitalization for FN and evidence supports the 
safety and efficacy of outpatient management[6-8], yet these do not seem to be 
translating into less hospitalizations for this population based on this nationally 
representative analysis.  
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 The proportion of patients with a SLOS among all FN discharges has remained 
relatively steady, 39% in 2012 from 41% in 2009. For all FN discharges, the mean LOS 
has gone up slightly from 7.1 days in 2009 to 7.5 days in 2012, contrary to the previously 
published multi-institution study by Basu, et al that had found a 3% decrease in LOS for 
FN per year.[20]  
This database provides a unique way in which to monitor the hospital trends for 
children with cancer who experience febrile neutropenia. If risk stratification schemas are 
implemented nationally, we should expect to see a decrease in the proportion of FN 
admissions among children with cancer as those who meet low risk criteria are beginning 
to receive outpatient therapy.  Similarly, if the step-down approach is implemented 
nationally (admission then discharge after a short observation period of observation, but 
prior to count recovery), the proportion of patients with a SLOS should increase.  Since 
the proportion of those who require medical interventions, other than intravenous 
antibiotics, will remain after 2-3 days. An interesting future evaluation utilizing the KID 
would be to assess how the associated diagnoses may change once ICD-10-CM codes are 
implemented, possibly leading to more granular information that can be ascertained from 
administrative databases. 
 While we do not believe it is feasible to use discharge diagnoses (ICD-9-CM 
codes) in order to devise triaging or new management styles, there are several consistent 
trends in both 2009 and 2012 that should be taken into consideration.  In both years 
analyses, it was found that having an oncologic diagnosis of soft tissue sarcoma or 
Hodgkin lymphoma was associated with having a SLOS, thus was associated with a very 
low proportion of serious infection diagnoses.  Patients with these diagnoses may 
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represent an ideal group for further evaluation and application of risk stratification 
schemas.  
 As clinically anticipated, infections were commonly found among discharges for 
FN, but serious infections remain uncommon among those patients with a SLOS.  In both 
the 2009 and 2012 analyses, ear infections were associated with having a SLOS. This 
likely represents a population of patients whose source of fever in the setting of 
neutropenia would be easily identified on careful examination. The question remains as 
to whether these findings were known prior to admission, which may depend on the 
comfort level of the provider doing the urgent care assessment. Pediatric providers are 
likely more comfortable examining the ears of young children and more highly trained in 
the diagnosis of ear infections. It would be intriguing to have more specific data about FN 
discharges where ear infections are diagnosed in order to determine if this population 
represents a low risk group who would be amenable to outpatient management.  
Mortality remains low among FN hospitalizations for children with cancer, 
currently found to be 0.5% as compared with 0.4% in 2009. The mortality rate among 
this nationally representative population is lower than previously documented.[20] While 
death will always remain an important outcome to monitor, it will need to be assessed as 
part of a larger set of outcomes given the very low incidence.[21] 
As evidenced by this analysis, the financial burden of FN care continues to climb. 
The average charges per FN discharge increased 26% from 2009 to 2012, with the overall 
charges for SLOS FN discharges increasing by almost 140%. This trend clearly 
demonstrates that efforts to decrease the number and length hospitalization for children 
with FN are necessary from a financial perspective. How children with cancer who 
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experience FN interact with the healthcare system is still not fully understood, as few 
datasets include pertinent patient and family level information regarding distance to 
treating institution, travel resources and institutional practices that can all impact the 
ability to treat low risk FN pediatric patients in the outpatient setting. The involvement of 
all stakeholders will ultimately be necessary to negotiate ways in which safety, efficacy, 
and cost are all taken into consideration.  
 While a major strength of this study is to provide a nationally representative 
overview of FN discharges for children with cancer, it has several important limitations.  
Administrative data analyses rely on accuracy of ICD-9-CM codes to identify the 
population and medical issues of interest, which are subject to errors of omission or 
commission. As described in our previous analysis, the type of admission was inferred 
based on discharge diagnoses.  FN is not a single diagnostic code, nor will it be in ICD-
10-CM, and was indicated by the presence of both ICD-9-CM codes for fever and 
neutropenia. It is also still possible that this was an underestimation of patients with FN 
given that some patients who present with fever and neutropenia may be discharged with 
only the diagnosis of neutropenia. We documented that the rates of FN discharges 
increased, but we did not analyze rates of discharges for other pediatric conditions, which 
may also have increased. We attempted to use the national census to adjust for changes in 
the population, due to the fact that there are no good data on the prevalence of childhood 
cancer, rather only incidence.  
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Conclusion 
Our updated study demonstrates that the impact of FN discharges among pediatric 
patients with cancer on healthcare utilization has continued to climb. As compared with 
our previous analysis, we have demonstrated that despite evidence supporting the 
feasibility and safety of alternative approaches to clinical management of FN, the burden 
upon the healthcare system has not improved. The continued documentation of the 
burden of FN will be key in expanding awareness and increasing motivation for a larger 
study to improve the care of pediatric patients with cancer experiencing FN.  
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